@misc{10481/110837,
year = {2019},
month = {6},
url = {https://hdl.handle.net/10481/110837},
abstract = {Poly(ADP-ribose) polymerase 3 (PARP3) is the third member of the PARP family that catalyze
a post-translational modification of proteins to promote, control or adjust numerous cellular
events including genome integrity, transcription, differentiation, cell metabolism or cell death.
In the late years, PARP3 has been specified for its primary functions in programmed and stressinduced
double-strand break repair, chromosomal rearrangements, transcriptional regulation in
the zebrafish and mitotic segregation. Still, deciphering the therapeutic value of its inhibition
awaits additional investigations. In this review, we discuss the newest advancements on the
specific functions of PARP3 in cancer aggressiveness exemplifying the relevance of its selective
inhibition for cancer therapy.},
organization = {Association pour la Recherche contre le Cancer},
organization = {Ligue Nationale Contre le Cancer},
organization = {CNRS},
organization = {Université de Strasbourg},
organization = {Ramon Areces Foundation},
organization = {LABEX ANR-10-LABX-0034_Medalis},
publisher = {Taylor & Francis},
keywords = {Poly (ADP-ribose) polymerase 3},
keywords = {mTORC2},
keywords = {cancer aggressiveness},
title = {PARP3 comes to light as a prime target in cancer therapy},
doi = {10.1080/15384101.2019.1617454},
author = {Rodríguez-Vargas, José Manuel and Nguekeu-Zebaze, Léonel and Dantzer, Francoise},
}